Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02039323 · ClinicalTrials.gov registry record · Phase 1
A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02039323 is a Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 6 participants.
The verdict
NCT02039323, a Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the feasibility of a novel method to assess antiretroviral efficacy for protection against HIV-1 infection in vaginal and cervical tissue biopsies.
Interventions
- DRUG Maraviroc
- DRUG Tenofovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02039323
The ClinicalTrials.gov registry entry for NCT02039323 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Maraviroc is the first listed.
NCT02039323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02039323 about?
NCT02039323 is a clinical study titled "A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants". The purpose of this study is to determine the feasibility of a novel method to assess antiretroviral efficacy for protection against HIV-1 infection in vaginal and cervical tissue biopsies.
What is the current status of trial NCT02039323?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2014-02. Estimated completion is 2014-04.
What interventions are being tested in trial NCT02039323?
The interventions under investigation include: Maraviroc (DRUG), Tenofovir (DRUG).
Who is sponsoring clinical trial NCT02039323?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.